Chester County News and Community Website
KING OF PRUSSIA, PA — CSL plans to seek approval to expand ANDEMBRY to children ages 2 through 11 after a Phase 3b study found most participants remained free of …
CSL Plans Pediatric ANDEMBRY Filing After Phase 3b Data Read More KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) said it has broken ground on a $1.5 billion expansion of its manufacturing facility in Kankakee, Illinois, aimed at increasing …
CSL Breaks Ground on $1.5 Billion Illinois Manufacturing Expansion Read More KING OF PRUSSIA, PA — The U.S. Food and Drug Administration (FDA) has approved ANDEMBRY® (garadacimab-gxii), developed by CSL, as the first treatment targeting factor XIIa for the prevention of …
FDA Approves ANDEMBRY® for Preventing Hereditary Angioedema Attacks Read More KING OF PRUSSIA, PA — CSL (ASX: CSL; USOTC: CSLLY) has unveiled four-year results from its pivotal HOPE-B study, demonstrating the long-term durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb), the …
CSL Reports Promising Four-Year Data on Gene Therapy for Hemophilia B Read More